CTOs on the Move

Integrated Viral Protection

www.ivpair.com

 
World-Leading Biodefense Indoor Air Protection System™ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ivpair.com
  • 7670, Woodway Drive
    Houston, TX USA 77063
  • Phone: 800.713.4872

Executives

Name Title Contact Details

Similar Companies

Highlands Community Services

Current Operational Status: A Letter from the Executive Director July 6, 2020 These last few [...]

FloraWorks

FloraWorks is a biotech enterprise that specializes in discovering rare and novel cannabinoids for commercial and therapeutic applications. They develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use...

Esperion

Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren`t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion commercializes NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets and is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol.

Kiel Laboratories

Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.